Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) said on Tuesday that its Japanese partner Eisai Co Ltd (TYO:4523) has presented new five-year data from the Clarity AD study and its long-term extension, showing increasing clinical benefit with continuous Leqembi treatment in early Alzheimer's disease.
The data, presented at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, also showed that 62% of patients treated at an earlier stage of disease, with low levels of tau, showed improvement in cognitive function and activities of daily living (CDR-SB) after five years.
Clarity AD is a global, placebo-controlled, double-blind, parallel-group, randomised Phase 3 study involving 1,795 patients with early Alzheimer's disease: 898 in the Leqembi group, receiving 10 mg/kg by intravenous infusion every two weeks, and 897 in the placebo group. Of the patients who completed the 18-month core study, 95% chose to participate in the subsequent long-term extension study. A total of 351 patients received five years of continuous treatment. The results support the importance of initiating treatment early in the course of Alzheimer's disease and continuing treatment to sustain the benefit over time.
No new safety findings were observed during five years of continuous Leqembi treatment.
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Eisai launches subcutaneous Leqembi Pen in Japan for early Alzheimer's disease
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia